Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company s...

Cipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growin...

Cipla shares: Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates re...

UBS has maintained a buy rating on Maruti, lowering the target price to Rs 14,800 despite Q2 results missing expectations. Improved demand ...

Cipla's shares are in focus as the company reported a 15% YoY increase in consolidated net profit to Rs 1,303 crore for Q2 2024. Revenue ro...

Cipla, incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 89460.16 Crore) operating in Pharmaceuticals sector.

Jefferies said the company's margins could jump to 31-32% for FY24-25 against 13% in FY22. "During Covid, IHCL has deployed several measure...

Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding th...

Cipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 72586.73 Crore) operating in Pharmaceuticals s...

Phillip Capital expects 8.1 per cent YoY growth in net profit of Cipla.

The generic would be used for treatment of asthma and chronic obstructive pulmonary disease.

Buy Cipla Ltd. at a price target of Rs 605.